On the afternoon of January 11, 2023, Shao Yuanchang, First-Class Inspector of the Provincial Drug Administration, led a team to visit Zhejiang Benefit Pharmaceutical to carry out the "Large-Scale Visit, Research, Service, and Problem-Solving" activity. Zhou Jirong, Member of the Party Leadership Group and Deputy Director of Lishui Municipal Market Supervision Bureau, accompanied the research. Wu Lihua, Chairman of the company, and relevant senior leaders warmly received the team.

Zhang Liyun, Deputy General Manager of the company, introduced various production links and R&D situations through a remote real-time video system, and gave a brief report on the development of the company's four business sectors, corporate culture, and Benefit's future layout plan for the extension of the traditional Chinese medicine industry.

At the forum, Chairman Wu Lihua first extended a warm welcome to First-Class Inspector Shao Yuanchang of the Provincial Drug Administration, Zhou Jirong, Member of the Party Leadership Group and Deputy Director of Lishui Municipal Market Supervision Bureau, and their entourage. He also expressed sincere gratitude to the Provincial Drug Administration and the Market Supervision Bureau for their consistent support and help during the enterprise's development. Meanwhile, he gave a detailed report on the current status of the enterprise's development and the production and filing of traditional Chinese medicine formula granules.

After listening to the report, Deputy Director Shao Yuanchang affirmed Benefit's unwavering original aspiration of devoting itself to the research and development of traditional Chinese medicine formula granules for more than ten years. Deputy Director Shao stated that as a local enterprise in Lishui focusing on the development of the traditional Chinese medicine industry, Benefit Pharmaceutical should be based on capacity improvement, rely on regional advantages to drive the common prosperity of Lishui's Chinese medicinal materials and medicinal farmers, and promote the healthy development of Lishui's Chinese medicinal materials industry.

The company's technical person in charge consulted on the blocking points, difficulties, and pain points encountered in the production process and the filing process of traditional Chinese medicine formula granules. The leading team answered questions on the spot and coordinated relevant responsible departments to help solve the problems encountered by Benefit at the current stage with care, effort, and sincerity.

At the end of the forum, Deputy Director Shao put forward three requirements for Benefit:

Strengthen policy research and maintain continuous compliance;

Improve the quality system and enhance management level;

Adhere to the characteristics of traditional Chinese medicine and continue to innovate and develop.

Subsequently, the group visited the logistics and warehousing center on site to gain an in-depth understanding of Benefit's products such as Chinese herbal pieces and traditional Chinese medicine formula granules.

As a practitioner, innovator, and inheritor in the traditional Chinese medicine formula granules industry, Zhejiang Benefit Pharmaceutical will remain true to its original aspiration, continue its mission, always uphold the corporate mission of "taking the essence of traditional Chinese medicine and promoting the culture of national quintessence", continuously innovate the development model of authentic medicinal materials, continue to explore the depth of traditional Chinese medicine products, achieve a new round of leap in innovative development, and take responsibility for building a healthy Lishui with the aim of ensuring higher-quality health for patients, contributing to the promotion of the revitalization and development of traditional Chinese medicine!